# The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC

> **NCT02344979** · — · UNKNOWN · sponsor: **Shenyang Sunshine Pharmaceutical Co., LTD.** · enrollment: 120 (estimated)

## Conditions studied

- Thrombocytopenia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02344979
- **Lead sponsor:** Shenyang Sunshine Pharmaceutical Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-05
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2015-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02344979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02344979, "The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02344979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*